Ascendis Pharma Management

Management Kriterienprüfungen 2/4

Ascendis Pharma CEO ist Jan Mikkelsen , ernannt in Dec 2007, hat eine Amtszeit von 16.92 Jahren. besitzt direkt 0.71% der Aktien des Unternehmens, im Wert von $52.65M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 8.3 Jahre bzw. 6.8 Jahre.

Wichtige Informationen

Jan Mikkelsen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	16.9yrs
Eigentum des Geschäftsführers	0.7%
Durchschnittliche Amtszeit des Managements	8.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.8yrs

Jüngste Management Updates

Recent updates

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Geschäftsführer

Jan Mikkelsen (64 yo)

16.9yrs

Amtszeit

Mr. Jan Moller Mikkelsen serves as the Chief Executive Officer, President, Executive Director and Member of Executive Board of Ascendis Pharma A/S since December 2007. He is Director at Eyconis, Inc. He se...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jan Mikkelsen	President	16.9yrs	keine Daten	0.71% $ 52.6m
Scott Smith	CFO, Executive VP & Member of Executive Board	8.3yrs	keine Daten	0.0067% $ 499.5k
Lotte Sonderbjerg	Executive VP	16.9yrs	keine Daten	0.0031% $ 231.2k
Michael Jensen	Executive VP	11.4yrs	keine Daten	0.0032% $ 240.1k
Mads Bodenhoff	Senior VP of Finance & Principal Accounting Officer	less than a year	keine Daten	keine Daten
Timothy Lee	Senior Director of Investor Relations	no data	keine Daten	keine Daten
Flemming Jensen	Executive Vice President of Product Supply & Quality	9.3yrs	keine Daten	0.0031% $ 231.2k
Kennett Sprogoe	Executive VP and Head of Research & Product Development	8.8yrs	keine Daten	0.0048% $ 359.0k
Stina Singel	Executive VP & Head of Clinical Development for Oncology	2.8yrs	keine Daten	keine Daten
Joseph Kelly	Head of U.S. Commercial of Endocrinology	2.5yrs	keine Daten	keine Daten
Scott Holmes	Head of Global Commercial Strategy of Endocrinology	2.5yrs	keine Daten	keine Daten
Camilla Hartvig	Executive VP & Global Chief Commercial Officer	1.4yrs	keine Daten	keine Daten

8.3yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: ASNDDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jan Mikkelsen	President	16.9yrs	keine Daten	0.71% $ 52.6m
Albert Cha	Independent Chairman	10yrs	€139.72k	0.00065% $ 48.3k
William Fairey	Independent Director	2.2yrs	€73.01k	0% $ 0
Lisa Morrison	Independent Director	7.6yrs	€92.64k	0.00065% $ 48.3k
Lars Holtug	Independent Director	6yrs	€96.17k	0.0015% $ 110.8k
Siham Imani	Independent Director	2.2yrs	€69.48k	0% $ 0

6.8yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: ASNDDie Vorstandsmitglieder gelten als erfahren (6.8 Jahre durchschnittliche Amtszeit).

Ascendis Pharma Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

President notifies of intention to sell stock

President notifies of intention to sell stock

President notifies of intention to sell stock

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q3, 2024 Results on Nov 14, 2024

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Consensus revenue estimates fall by 19%

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Consensus EPS estimates fall by 13%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Consensus revenue estimates increase by 12%

Ascendis Pharma's Ambitious Vision 2030

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

President notifies of intention to sell stock

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

New major risk - Negative shareholders equity

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Consensus revenue estimates decrease by 11%

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Key Executive notifies of intention to sell stock

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Consensus revenue estimates increase by 24%

Independent Chairman notifies of intention to sell stock

New major risk - Financial position

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Consensus revenue estimates decrease by 14%

President notifies of intention to sell stock